Treatment with prasugrel according to EU label recommendations results in a significant 27 % and 57 % relative risk reduction ( absolute risk reductions of 2.7 % and 1.2 % ) in ischemic events and stent thromboses respectively compared with clopidogrel , with a 15 % relative risk increase ( absolute risk increase of 0.2 % ) for major bleeds ( p = 0.40 ) , and no excess of strokes .